VJHemOnc Podcast

The podcast explores the role of measurable residual disease (MRD) in the management of multiple myeloma. Topics discussed include the prognostic relevance of MRD, personalized approaches in myeloma maintenance treatment, the clinical benefits of mass spectrometry for detecting the monoclonal component, study results on treatment response and outcomes for multiple myeloma patients, and the complementarity of next generation sequencing and mass spectrometry in MRD testing.

This podcast discusses the latest updates and potential of CAR-T therapy for chronic lymphocytic leukemia (CLL), including the combination of CAR-T therapy with ebrutinib, eligibility criteria and safety of CAR-T therapy trial, promising results and high rates of undetectable minimal residual disease, and the potential of CAR-T therapy to cure CLL.

Experts discuss the treatment of elderly multiple myeloma patients, including advancements in myeloma treatment, assessing fitness and frailty, treatment approaches, and challenges in finding effective treatments.

Experts discuss challenges in treating older patients with ALL, diagnostic testing for Ph-like ALL, and interventions to prevent relapse after stem cell transplantation.

Speakers discuss their experiences as women in the MDS field, challenges faced by women in science, and the progress of MDS research. They explore the debate on curing MDS versus managing it, the potential of bone marrow transplants and cellular therapies, and the role of precision medicine in blood diseases.

Leading experts discuss the challenges and potential of CAR-T therapy for AML, including targeting CD33 and utilizing NK cells. They explore a case study involving T cell expansion and integration of CAR. Promising results from a phase one trial using NK cells are presented, along with advancements in incorporating NPM1 mutant protein into CAR and NK cells.

Leading researchers discuss evolving treatment strategies, novel therapies, and immune checkpoint inhibitors for myelodysplastic syndrome (MDS) presented at ASH 2020. They highlight the pros and cons of the virtual format, explore the future of MDS treatment including combination therapies, and discuss the administration and cost considerations of MDS treatments. The podcast also covers advancements in immune checkpoint inhibitors for solid tumors, the importance of early transplant for higher risk MDS patients, and the impact of COVID-19 on clinical research.

Experts discuss the management of post-transplant relapse and immune attack, focusing on graft-versus-host disease and cellular therapies. They highlight key studies from ASH 2020, including new agents for chronic GVHD, manufacturing and testing of NK cells, CD34 selected T-RiG graft, and CAR-T abstracts. They also cover highlights from ASH 2020 regarding myeloma, leukemia, and lymphoma studies, as well as the rapid growth in cellular therapies for multiple myeloma and future developments.

Leading experts Graham Collins discuss highlights from ASH 2020, including bispecific monoclonal antibodies for aggressive lymphomas, CMR rates and CAR-T data for high-grade lymphoma, CNS prophylaxis in diffuse large B-cell lymphoma, efficacy of treatment options for indolent lymphoma, checkpoint inhibition in Hodgkin lymphoma treatment, and highlights and controversies from the ASH 2020 conference.

Experts discuss the latest updates in Hodgkin lymphoma from ISHL HL 2021. Topics include the use of biomarkers in HL, innovative first-line therapies, and treatment options for relapsed or refractory disease.